Creating new proteins to improve cancer immunotherapy
Design of de novo interleukin mimics for targeted immunotherapy
This study is working on creating new types of proteins that can help your immune system better fight cancer while being safer and causing fewer side effects than current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10694869 on NIH RePORTER |
What this research studies
This research focuses on developing innovative protein mimics that can stimulate the immune system to target and destroy cancer cells more effectively and safely. By utilizing advanced protein design techniques, the project aims to create stable and non-toxic versions of natural cytokines, which are proteins that help regulate immune responses. The approach involves engineering these proteins to bind specifically to cancer cell markers, thereby minimizing side effects and enhancing treatment efficacy. Patients may benefit from therapies that are more effective and have fewer harmful effects compared to traditional cytokine treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with renal cell carcinoma or other malignancies that could benefit from targeted immunotherapy.
Not a fit: Patients with non-cancerous conditions or those who do not have specific cancer markers targeted by the engineered proteins may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective immunotherapy options for cancer patients.
How similar studies have performed: Other research has shown promise in using engineered proteins for targeted cancer therapies, indicating that this approach could be a viable advancement in cancer treatment.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Baker, David — University of Washington
- Study coordinator: Baker, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.